Pyruvate Kinase 5: A Potential Drug Target and Biomarker (G51646)

Target Name: YPEL5

NCBI ID: G51646

YPEL5

Pyruvate Kinase 5: A Potential Drug Target and Biomarker

YPEL5 (Yeast Pyruvate Kinase 5) is a gene that encodes a protein known as Pyruvate Kinase 5. This protein is a key player in the metabolic pathway, specifically the citric acid cycle, also known as the Krebs cycle or TCA cycle. It plays a crucial role in the production of energy from glucose and other simple sugars, and is a potential drug target in the treatment of various diseases.

The citric acid cycle is a central metabolic pathway that occurs in all eukaryotic cells. It is responsible for the production of energy from glucose and other simple sugars, as well as the production of various molecules, including amino acids, nucleotides, and lipids. The Pyruvate Kinase 5 protein is a key enzyme in this pathway, catalyzing the conversion of pyruvate to acetyl-CoA, which is then used to produce energy in the form of ATP.

Pyruvate Kinase 5 is a protein that is expressed in various tissues and cells throughout the body. It is highly conserved, with sequence homologs found in various species, including humans, yeast, and bacteria. It is also known to be involved in various cellular processes , including cell growth, differentiation, and stress response.

One of the potential benefits of targeting Pyruvate Kinase 5 is its involvement in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that inhibition of Pyruvate Kinase 5 has anti-tumor and anti-inflammatory effects in various cancer cell lines and animal models. Additionally, inhibition of Pyruvate Kinase 5 has been shown to protect against neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, in animal models.

Another potential mechanism by which Pyruvate Kinase 5 may contribute to various diseases is its role in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of oxidative stress-induced diseases. Pyruvate Kinase 5 has been shown to generate ROS in response to various stressors, including reactive oxygen species, which can then contribute to the development of oxidative stress-induced diseases.

In addition to its potential therapeutic applications, Pyruvate Kinase 5 is also a promising biomarker for the diagnosis and monitoring of various diseases. For example, the expression of Pyruvate Kinase 5 has been shown to be elevated in certain diseases, such as cancer and neurodegenerative diseases , and can be used as a diagnostic biomarker for these conditions. Additionally, the levels of Pyruvate Kinase 5 have been shown to be decreased in certain therapeutic interventions, such as cancer treatment, which can be used as a predictive biomarker for disease outcomes.

In conclusion, Pyruvate Kinase 5 is a gene that encodes a protein involved in the production of energy from glucose and other simple sugars. It is highly conserved and has been shown to be involved in various cellular processes and diseases. The potential therapeutic applications of Pyruvate Kinase 5 make it an attractive target for further research and development. Further studies are needed to fully understand the role of Pyruvate Kinase 5 in various diseases and to develop safe and effective therapies based on its targeting.

Protein Name: Yippee Like 5

Functions: Component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). Required for normal cell proliferation (By similarity)

The "YPEL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YPEL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets